A Phase 3 interventional study of Trastuzumab Deruxtecan and Paclitaxel in Breast Neoplasms, Breast Cancer and HER2-positive Early Breast Cancer, sponsored by AstraZeneca. Active, not recruiting at 145 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies testing trastuzumab deruxtecan in Breast Neoplasms — 31 open to participants now, 45 under way, 8 of them phase 3. trastuzumab deruxtecan · Breast Neoplasms.
Among the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms, this one is the 3rd largest by enrollment, is one of 3 that started in 2021, is one of 12 in phase 3, reaches primary completion later than 5 of the 44 other live ones, and was the 21st registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →31 of the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Daiichi Sankyo · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
SOLTI Breast Cancer Research Group · Sites in France, Germany, Spain
Ages 18+
Kristina A. Fanucci · Sites in United States
Ages 18+
Institut Claudius Regaud · Sites in France
Ages 18+
By country, each count listing its studies:
trastuzumab deruxtecan: first FDA approval 2019 (ENHERTU), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, trastuzumab deruxtecan is the treatment under test here. Read study by study →
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 37 · Phase 3 12 · Phase 4 2
First in 2017; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 927 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 139 across the 58 interventional studies. Of the 12 that completed or were terminated, 10 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 58 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
198 studies in Breast Neoplasms by AstraZeneca: 20 open now, 50 under way, 24 of them phase 3. Of 144 finished, 32 (22%) have results posted.
Among the 198 studies in Breast Neoplasms by AstraZeneca, this one is the 13th largest by enrollment of the 125 interventional ones that give a count, is one of 13 that started in 2021, is one of 46 in phase 3, reaches primary completion later than 11 of the 49 other live ones, and was the 150th registered.
AstraZeneca’s Breast Neoplasms studies by the year they started, since 1996.
13 of the studies testing trastuzumab deruxtecan in Breast Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04784715Phase 3AstraZenecaTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | 2027-05-03 |
| NCT05950945Phase 3Daiichi SankyoTrastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer | 2027-10-01 |
| NCT06048718MedSIRT-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases | 2026-11 |
| NCT04553770Jonsson Comprehensive Cancer CenterTrastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer | 2026-12-31 |
| NCT06486883MedSIRSafety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype | 2027-01 |
Add all 13 to your calendar (.ics) → With an account.
Among the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms, from their registry updates:
Among AstraZeneca’s 198 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This study will look at the efficacy and safety of trastuzumab deruxtecan (T-DXd) in a neoadjuvant setting, in high-risk, HER2-positive early non-metastatic breast cancer.
The target population of interest in this study is participants with high-risk HER2-positive early-stage breast cancer. The purpose of this study is to determine the efficacy and safety of T-DXd neoadjuvant therapy.
Participants will be randomised to one of 3 arms: T-DXd monotherapy (Arm A), T-DXd followed by THP (Arm B), or ddAC-THP (Arm C).
Key Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Trastuzumab deruxtecan
Drug: Trastuzumab Deruxtecan
T-DXd, followed by THP
Drug: Trastuzumab Deruxtecan · Drug: Paclitaxel · Drug: Trastuzumab · Drug: Pertuzumab
doxorubicin and cyclophosphamide, followed by THP
Drug: Paclitaxel · Drug: Trastuzumab · Drug: Pertuzumab · Drug: Doxorubicin · Drug: cyclophosphamide
administered by intravenous infusion
Also known as: T-DXd, Enhertu
administered by intravenous infusion
Also known as: Taxol, Onxol
administered by intravenous infusion
Also known as: Herceptin, Herzuma
administered by intravenous infusion
Also known as: Perjeta
administered by intravenous infusion
Also known as: Adriamycin, Rubex
administered by intravenous infusion
Also known as: Neosar, Cytoxan
Rate of Pathologic Complete Response (pCR).
Proportion of participants who have no evidence by Hematoxylin \& Eosin (H\&E) staining of residual invasive disease in the complete resected breast specimen and all sampled regional lymph nodes (ypT0/Tis ypN0) by central evaluation following completion of neoadjuvant therapy.
Time frame: Through to definitive surgery or discontinuation/withdrawal from study, up to a maximum of approximately 40 months from randomization to primary pCR DCO (12MAR2025)
Event-Free Survival (Count)
Event-free survival (EFS) is defined as the time from date of randomization until disease progression precluding initial surgery, invasive disease recurrence (local, regional, distant, or contralateral), or death from any cause.
Time frame: Up to a maximum of approximately 65 months from randomization to EFS final analysis DCO (Apr 2027)
Event-Free Survival (Duration)
Event-free survival (EFS) is defined as the time from date of randomization until disease progression precluding initial surgery, invasive disease recurrence (local, regional, distant, or contralateral), or death from any cause.
Time frame: Up to a maximum of approximately 65 months from randomization to EFS final analysis DCO (Apr 2027)
The study is active, not recruiting and conducted in 18 countries worldwide across 147 centres, with 927 patients who were randomized up until 24th April 2024. Results are reported for the study at the data cut-off for the primary analysis for pathologic complete response (pCR) on 12th March 2025.
| Milestone | Arm A | Arm B | Arm C |
|---|---|---|---|
| Started | 286 | 321 | 320 |
| Completed | 0 | 0 | 0 |
| Not completed | 286 | 321 | 320 |
| Withdrew: Death | 8 | 3 | 9 |
| Withdrew: Withdrawal by subject | 11 | 4 | 21 |
| Withdrew: As recorded on the case report form (crf). | 1 | 1 | 2 |
| Withdrew: Ongoing at the time of primary analysis for pcr | 266 | 313 | 288 |
Proportion of participants who have no evidence by Hematoxylin \& Eosin (H\&E) staining of residual invasive disease in the complete resected breast specimen and all sampled regional lymph nodes (ypT0/Tis ypN0) by central evaluation following completion of neoadjuvant therapy.
| Percentage of participants | Arm A | Arm B | Arm C |
|---|---|---|---|
| Rate of Pathologic Complete Response (pCR). | 43.01 | 67.29 | 56.25 |
Event-free survival (EFS) is defined as the time from date of randomization until disease progression precluding initial surgery, invasive disease recurrence (local, regional, distant, or contralateral), or death from any cause.
Results for this outcome have not been posted.
Event-free survival (EFS) is defined as the time from date of randomization until disease progression precluding initial surgery, invasive disease recurrence (local, regional, distant, or contralateral), or death from any cause.
Results for this outcome have not been posted.
Collected over All-cause mortality: from date of randomization through to death due to any cause. Adverse events and SAEs are reported from the first dose date, throughout the treatment period and the safety follow-up period (until 40 + 7 days after the discontinuation of all study interventions). Both up to a maximum of approximately 40 months to primary pCR DCO (12MAR2025).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| T-DXd | 8/286 (2.8%) | 29/283 (10.2%) | 269/283 (95.1%) |
| T-DXd-THP | 3/321 (0.9%) | 34/320 (10.6%) | 306/320 (95.6%) |
| ddAC-THP | 9/320 (2.8%) | 63/312 (20.2%) | 307/312 (98.4%) |
| Event | T-DXd | T-DXd-THP | ddAC-THP |
|---|---|---|---|
| PneumoniaInfections and infestations | 3/283 | 1/320 | 9/312 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 1/283 | 4/320 | 7/312 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/283 | 1/320 | 7/312 |
| AnaemiaBlood and lymphatic system disorders | 1/283 | 0/320 | 5/312 |
| MyelosuppressionBlood and lymphatic system disorders | 0/283 | 0/320 | 5/312 |
| NeutropeniaBlood and lymphatic system disorders | 0/283 | 0/320 | 5/312 |
| PyrexiaGeneral disorders | 0/283 | 2/320 | 4/312 |
| Covid-19Infections and infestations | 3/283 | 3/320 | 3/312 |
| Alanine aminotransferase increasedInvestigations | 0/283 | 2/320 | 3/312 |
| Aspartate aminotransferase increasedInvestigations | 0/283 | 0/320 | 3/312 |
| Event | T-DXd | T-DXd-THP | ddAC-THP |
|---|---|---|---|
| NauseaGastrointestinal disorders | 193/283 | 207/320 | 161/312 |
| DiarrhoeaGastrointestinal disorders | 64/283 | 187/320 | 168/312 |
| AlopeciaSkin and subcutaneous tissue disorders | 120/283 | 152/320 | 153/312 |
| AnaemiaBlood and lymphatic system disorders | 42/283 | 73/320 | 152/312 |
| ConstipationGastrointestinal disorders | 95/283 | 93/320 | 76/312 |
| VomitingGastrointestinal disorders | 87/283 | 91/320 | 66/312 |
| StomatitisGastrointestinal disorders | 39/283 | 59/320 | 86/312 |
| FatigueGeneral disorders | 66/283 | 74/320 | 82/312 |
| Neuropathy peripheralNervous system disorders | 11/283 | 83/320 | 65/312 |
| Alanine aminotransferase increasedInvestigations | 63/283 | 77/320 | 80/312 |
This population includes all randomized patients.
| Age, Categorical(Participants) | Arm A | Arm B | Arm C | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 252 | 282 | 288 | 822 |
| >=65 years | 34 | 39 | 32 | 105 |
| Age, Continuous(Years) | Arm A | Arm B | Arm C | Total |
|---|---|---|---|---|
| Mean | 50.3 ± 11.25 | 50.0 ± 11.09 | 50.1 ± 11.32 | 50.1 ± 11.21 |
| Sex: Female, Male(Participants) | Arm A | Arm B | Arm C | Total |
|---|---|---|---|---|
| Female | 286 | 321 | 320 | 927 |
| Male | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Arm A | Arm B | Arm C | Total |
|---|---|---|---|---|
| Hispanic or Latino | 28 | 29 | 28 | 85 |
| Not Hispanic or Latino | 257 | 292 | 292 | 841 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Arm A | Arm B | Arm C | Total |
|---|---|---|---|---|
| Black or African American | 7 | 5 | 7 | 19 |
| Native Hawaiian or other Pacific Islander | 0 | 1 | 1 | 2 |
| American Indian or Alaska Native | 2 | 2 | 0 | 4 |
| Asian | 127 | 160 | 157 | 444 |
| White | 139 | 140 | 137 | 416 |
| Other | 6 | 9 | 9 | 24 |
| Not reported | 5 | 4 | 9 | 18 |
| Height(cm) | Arm A | Arm B | Arm C | Total |
|---|---|---|---|---|
| Mean | 160.248 ± 7.0934 | 159.793 ± 6.8713 | 160.441 ± 7.1728 | 160.158 ± 7.0434 |
| Weight(kg) | Arm A | Arm B | Arm C | Total |
|---|---|---|---|---|
| Mean | 66.212 ± 15.2465 | 64.879 ± 12.3807 | 66.284 ± 14.5867 | 65.776 ± 14.0814 |
| BMI(kg/m2) | Arm A | Arm B | Arm C | Total |
|---|---|---|---|---|
| Mean | 25.717 ± 5.3100 | 25.383 ± 4.6143 | 25.724 ± 5.2130 | 25.604 ± 5.0432 |
2 further baseline measures are reported on the registry.
Showing the first 100 of 145 sites across 18 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient data from AstraZeneca Group of Companies, sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ Disclosure Commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Access criteria: When a request has been approved, AstraZeneca will provide access to the de-identified patient level data in an approved sponsor tool. Signed Data Sharing Agreements (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Ran from Oct 2021 to primary completion in Mar 2025, 40 months.
Results were first posted in Jun 2026, 1 year 2 months after primary completion.
Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 40 months is close to that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Trastuzumab deruxtecan · Trastuzumab